Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy

Liu,Wenjuan; Zhang,Lingyun; Shi,Jing; Liu,Yunpeng; Zhou,Lizhong; Hou,Kezuo; Qu,Xiujuan; Teng,Yuee

doi:10.3892/ol.2015.2965

Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy

Authors:
- Wenjuan Liu
- Lingyun Zhang
- Jing Shi
- Yunpeng Liu
- Lizhong Zhou
- Kezuo Hou
- Xiujuan Qu
- Yuee Teng
View Affiliations

Affiliations: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Medical Oncology, The Tumor Hospital of Anshan City, Anshan, Liaoning 114034, P.R. China
Published online on: February 16, 2015 https://doi.org/10.3892/ol.2015.2965
Pages: 1707-1714

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of phosphorylated Akt (pAkt) and phosphorylated extracellular‑regulated kinase 1/2 (pErk1/2) proteins may result in breast cancer progression and drug resistance in vitro, however, compelling evidence regarding the clinical significance of pAkt and pErk1/2 in early‑stage breast cancer is currently lacking. Thus, the aim of the present study was to determine the prognostic value of pAkt and pErk1/2 expression in early‑stage breast cancer patients treated with anthracycline‑based adjuvant chemotherapy. Tumor specimens were obtained from 256 patients with early‑stage breast cancer who had been treated with anthracycline‑based adjuvant chemotherapy, and pAkt and pErk1/2 protein expression was immunohistochemically determined. The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ2 tests, and survival functions were estimated using the Kaplan‑Meier method. It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001). In addition, after a median follow‑up period of 52.5 months, the patients with pAkt‑ and pErk1/2‑negative tumors experienced a significantly longer disease‑free survival (DFS) time compared with pAkt‑ or pErk1/2‑positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)‑positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016). Thus, the coexpression of pAkt and pErk1/2 was an independent factor for a poor prognosis in early‑stage and HER2‑positive breast cancer patients. By contrast, pErk1/2 expression alone may be a poor predictor for determining the efficacy of anthracycline‑based chemotherapy.

View Figures

View References

1	Fan L, Strasser-Weippl K, Li JJ, et al: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
2	Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 21:3357–3365. 2003. View Article : Google Scholar : PubMed/NCBI
3	Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
4	Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
5	Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE and Lee JM: eEF1A2 activates AKT and stimulates AKT-dependent actin remodeling, invasion and migration. Oncogene. 26:3027–3040. 2007. View Article : Google Scholar
6	Srinivasan S, Koduru S, Kumar R, et al: Diosgenin targets AKT-mediated prosurvival signaling in human breast cancer cells. Int J Cancer. 125:961–967. 2009. View Article : Google Scholar : PubMed/NCBI
7	Andre F, Nahta R, Conforti R, et al: Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol. 19:315–320. 2008. View Article : Google Scholar
8	Tokunaga E, Kimura Y, Oki E, et al: Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer. 118:284–289. 2006. View Article : Google Scholar
9	Schmitz KJ, Otterbach F, Callies R, et al: Prognostic relevance of activated AKT kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol. 17:15–21. 2004. View Article : Google Scholar
10	Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB and Fan Z: Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin and gemcitabine. Mol Pharmacol. 70:1045–1052. 2006. View Article : Google Scholar : PubMed/NCBI
11	Knuefermann C, Lu Y, Liu B, et al: HER2/PI-3k/AKT activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003. View Article : Google Scholar : PubMed/NCBI
12	Li X, Lu Y, Liang K, Liu B and Fan Z: Differential responses to doxorubicin-induced phosphorylation and activation of AKT in human breast cancer cells. Breast Cancer Res. 7:R589–R597. 2005. View Article : Google Scholar : PubMed/NCBI
13	Roudier E, Mistafa O and Stenius U: Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther. 5:2706–2715. 2006. View Article : Google Scholar : PubMed/NCBI
14	Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 10:7031–7042. 2004. View Article : Google Scholar : PubMed/NCBI
15	Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 80:239–256. 2002. View Article : Google Scholar : PubMed/NCBI
16	McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
17	Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V and Löning T: Expression and prognostic relevance of activated extracellular regulated kinases (ERK1/2) in breast cancer. Br J Cancer. 92:2206–2215. 2005. View Article : Google Scholar : PubMed/NCBI
18	Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F and Eppenberger U: Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer. 89:384–388. 2000. View Article : Google Scholar : PubMed/NCBI
19	Gee JM, Robertson JF, Ellis IO and Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 95:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
20	Eralp Y, Derin D, Ozluk Y, et al: MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol. 19:669–674. 2008. View Article : Google Scholar
21	Glück S, de Snoo F, Peeters J, et al: Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 139:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
22	Glück S, Ross JS, Royce M, et al: TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat. 132:781–791. 2012. View Article : Google Scholar
23	Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI
24	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
25	Lee ER, Kim JY, Kang YJ, et al: Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta. 1763:958–968. 2006. View Article : Google Scholar : PubMed/NCBI
26	Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 357:39–51. 2007. View Article : Google Scholar : PubMed/NCBI
27	Meric-Bernstam F and Hung MC: Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 12:6326–6330. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K and Seliger B: Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res. 85:101–144. 2002. View Article : Google Scholar : PubMed/NCBI
29	Hung MC and Lau YK: Basic science of HER-2/neu: a review. Semin Oncol. 26(Suppl 12): 51–59. 1999.PubMed/NCBI
30	Park SS and Kim SW: Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Oncol Rep. 18:139–143. 2007.PubMed/NCBI
31	Gori S, Sidoni A, Colozza M, et al: EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol. 20:648–654. 2009. View Article : Google Scholar : PubMed/NCBI
32	Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 1:707–717. 2002.PubMed/NCBI
33	Esteva FJ, Sahin AA, Smith TL, et al: Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node positive breast carcinoma. Cancer. 100:499–506. 2004. View Article : Google Scholar : PubMed/NCBI
34	Morse MA, Wei J, Hartman Z, et al: Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer. 126:2893–2903. 2010.
35	Johnston SR: Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int J Gynecol Cancer. 16(Suppl 2): 543–548. 2006. View Article : Google Scholar : PubMed/NCBI